Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
167%(5 trials)
Terminated
2(40%)

Phase Distribution

Ph phase_2
1
20%
Ph phase_3
2
40%
Ph phase_4
2
40%

Phase Distribution

0

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
2(40.0%)
Phase 4Post-market surveillance
2(40.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Terminated(2)

Detailed Status

Completed3
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
60.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (20.0%)
Phase 32 (40.0%)
Phase 42 (40.0%)

Trials by Status

terminated240%
completed360%

Recent Activity

0 active trials
Showing 5 of 5
terminatedphase_3

Tapentadol in Chronic Malignant Tumour Related Pain

NCT01264887
completedphase_4

Comparison of Increasing Doses of Tapentadol Versus a Combination of Tapentadol and Pregabalin

NCT01352741
completedphase_2

A Study to Look at Tapentadol Tablets in Children and Adolescents in Pain

NCT02151682
terminatedphase_3

Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking WHO Step III Analgesics But Showing a Lack of Tolerability

NCT00986258
completedphase_4

Tapentadol Prolonged Release (PR) Versus Oxycodone/Naloxone Prolonged Release in Severe Chronic Low Back Pain With a Neuropathic Component.

NCT01838616

Clinical Trials (5)

Showing 5 of 5 trials
NCT01264887Phase 3

Tapentadol in Chronic Malignant Tumour Related Pain

Terminated
NCT01352741Phase 4

Comparison of Increasing Doses of Tapentadol Versus a Combination of Tapentadol and Pregabalin

Completed
NCT02151682Phase 2

A Study to Look at Tapentadol Tablets in Children and Adolescents in Pain

Completed
NCT00986258Phase 3

Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking WHO Step III Analgesics But Showing a Lack of Tolerability

Terminated
NCT01838616Phase 4

Tapentadol Prolonged Release (PR) Versus Oxycodone/Naloxone Prolonged Release in Severe Chronic Low Back Pain With a Neuropathic Component.

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5